Non-Neoplastic Cellular Binding of PSMA-Targeted Probes Limits Radiation Dose Delivery and Therapeutic Efficacy in Glioma (EANM 2026) - Sep 29, 2026 - Abstract #OP-314; Pres time: Oct 19, 2026; 08:00 AM - 09:30 AM; Location: Hall F1; "Pathology-informed dosimetry simulations estimated radiation dose delivered to tumor nuclei by 177Lu- and 225Ac-PSMA-617 using the dose-point-kernel method, with tumor cell survival modeled by the linear-quadratic approach... In glioma, PSMA-targeted probes predominantly bind to non-neoplastic cells, creating a fundamental dosimetric barrier that explains therapeutic failure despite high PET uptake. These findings necessitate integrating cellular target validation and preemptive dosimetry into theranostic agent development."
Clinical • Brain Cancer • Genito-urinary Cancer • Glioma • Prostate Cancer • Solid Tumor • FOLH1
|
|
R. Yang; K. Guo; G. Li; J. Ye; K. Yu; T. Ma; J. Wang; Y. Guo; F. Kang; J. Wang
|